Ads
related to: sglt2 inhibitor adverse effects
Search results
Results From The WOW.Com Content Network
Dapagliflozin is an example of an SGLT-2 inhibitor, it is a competitive, highly selective inhibitor of SGLT. It acts via selective and potent inhibition of SGLT-2, and its activity is based on each patient's underlying blood sugar control and kidney function. The results are decreased kidney reabsorption of glucose, glucosuria effect increases ...
It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. [1] It is taken by mouth. [1] The most common side effect is genital infection in women. [2] Other common side effects include diabetic ketoacidosis, diarrhea, and genital infection in men. [2]
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar loss in urine. [ 2 ] Empagliflozin was approved for medical use in the United States and in the European Union in 2014.
Other diabetes drugs, specifically sodium-glucose cotransporter 2 (SGLT2) inhibitors, can also lead to a reduction in lean mass. This includes canagliflozin (Invokana®) and dapagliflozin (Farxiga®).
The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . [5] [6] The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).
[3] [4] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is taken by mouth. [1] [2] The most common side effects include genital yeast infections, urinary tract infections, and increased urination. [4] Bexagliflozin was approved for medical use in the United States in January 2023. [4] [5]
Adverse effects [ edit ] To reduce the risk of developing ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medications, recommending they be temporarily stopped before scheduled surgery.